SBFM PE Ratio & Valuation,Is SBFM Overvalued

SBFM Relative Valuation

SBFM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SBFM is overvalued; if below, it's undervalued.

Historical Valuation

Sunshine Biopharma Inc (SBFM) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.57. The fair price of Sunshine Biopharma Inc (SBFM) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：1.39

Fair

-2.80

0.00

EV/EBITDA

Sunshine Biopharma Inc. (SBFM) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

0.70

EV/EBIT

Sunshine Biopharma Inc. (SBFM) has a current EV/EBIT of 0.70. The 5-year average EV/EBIT is 0.95. The thresholds are as follows: Strongly Undervalued below -5.92, Undervalued between -5.92 and -2.48, Fairly Valued between 4.39 and -2.48, Overvalued between 4.39 and 7.82, and Strongly Overvalued above 7.82. The current Forward EV/EBIT of 0.70 falls within the Historic Trend Line -Fairly Valued range.

0.15

Sunshine Biopharma Inc. (SBFM) has a current PS of 0.15. The 5-year average PS is 0.14. The thresholds are as follows: Strongly Undervalued below -0.32, Undervalued between -0.32 and -0.09, Fairly Valued between 0.37 and -0.09, Overvalued between 0.37 and 0.61, and Strongly Overvalued above 0.61. The current Forward PS of 0.15 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Sunshine Biopharma Inc. (SBFM) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.

0.00

P/FCF

Sunshine Biopharma Inc. (SBFM) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Sunshine Biopharma Inc (SBFM) has a current Price-to-Book (P/B) ratio of 0.26. Compared to its 3-year average P/B ratio of 0.34 , the current P/B ratio is approximately -22.63% higher. Relative to its 5-year average P/B ratio of 0.20, the current P/B ratio is about 29.55% higher. Sunshine Biopharma Inc (SBFM) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -180.27%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -111.02% , the current FCF yield is about -100.00% lower.

0.26

P/B

Median3y

0.34

Median5y

0.20

-108.59

FCF Yield

Median3y

-180.27

Median5y

-111.02

Competitors Valuation Multiple

The average P/S ratio for SBFM's competitors is 0.00, providing a benchmark for relative valuation. Sunshine Biopharma Inc Corp (SBFM) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 11.64%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of SBFM decreased by 54.00% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 8.44M to 9.42M.

The secondary factor is the P/E Change, contributed -31.77%to the performance.

Overall, the performance of SBFM in the past 1 year is driven by Revenue Growth. Which is more sustainable.

11.64%

8.44M → 9.42M

Revenue Growth

-33.87%

-14.20 → -9.39

Margin Expansion

-31.77%

-1.18 → -0.80

P/E Change

-54.00%

3.00 → 1.38

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Sunshine Biopharma Inc (SBFM) currently overvalued or undervalued?

What is Sunshine Biopharma Inc (SBFM) fair value?

SBFM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Sunshine Biopharma Inc (SBFM) is between NaN to NaN according to relative valuation methord.

How does SBFM's valuation metrics compare to the industry average?

What is the current P/B ratio for Sunshine Biopharma Inc (SBFM) as of Dec 17 2025?

As of Dec 17 2025, Sunshine Biopharma Inc (SBFM) has a P/B ratio of 0.26. This indicates that the market values SBFM at 0.26 times its book value.

What is the current FCF Yield for Sunshine Biopharma Inc (SBFM) as of Dec 17 2025?

As of Dec 17 2025, Sunshine Biopharma Inc (SBFM) has a FCF Yield of 0.00%. This means that for every dollar of Sunshine Biopharma Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Sunshine Biopharma Inc (SBFM) as of Dec 17 2025?

As of Dec 17 2025, Sunshine Biopharma Inc (SBFM) has a Forward P/E ratio of -2.82. This means the market is willing to pay $-2.82 for every dollar of Sunshine Biopharma Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Sunshine Biopharma Inc (SBFM) as of Dec 17 2025?

As of Dec 17 2025, Sunshine Biopharma Inc (SBFM) has a Forward P/S ratio of 0.00. This means the market is valuing SBFM at $0.00 for every dollar of expected revenue over the next 12 months.

SBFM Valuation

SBFM Valuation

SBFM Relative Valuation

Historical Valuation

Competitors Valuation Multiple

Performance Decomposition

People Also Watch

Frequently Asked Questions

Is Sunshine Biopharma Inc (SBFM) currently overvalued or undervalued?

What is Sunshine Biopharma Inc (SBFM) fair value?

How does SBFM's valuation metrics compare to the industry average?

What is the current P/B ratio for Sunshine Biopharma Inc (SBFM) as of Dec 17 2025?

What is the current FCF Yield for Sunshine Biopharma Inc (SBFM) as of Dec 17 2025?

What is the current Forward P/E ratio for Sunshine Biopharma Inc (SBFM) as of Dec 17 2025?

What is the current Forward P/S ratio for Sunshine Biopharma Inc (SBFM) as of Dec 17 2025?